SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.
Tea, F
Ospina Stella, A
Aggarwal, A
Ross Darley, D
Pilli, D
Vitale, D
Merheb, V
Lee, FXZ
Cunningham, P
Walker, GJ
Fichter, C
Brown, DA
Rawlinson, WD
Isaacs, SR
Mathivanan, V
Hoffmann, M
Pöhlman, S
Mazigi, O
Christ, D
Dwyer, DE
Rockett, RJ
Sintchenko, V
Hoad, VC
Irving, DO
Dore, GJ
Gosbell, IB
Kelleher, AD
Matthews, GV
Brilot, F
Turville, SG
- Publisher:
- Public Library of Science (PLoS)
- Publication Type:
- Journal Article
- Citation:
- PLoS medicine, 2021, 18, (7), pp. e1003656
- Issue Date:
- 2021-07-06
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Tea, F | |
dc.contributor.author | Ospina Stella, A | |
dc.contributor.author | Aggarwal, A | |
dc.contributor.author | Ross Darley, D | |
dc.contributor.author | Pilli, D | |
dc.contributor.author | Vitale, D | |
dc.contributor.author | Merheb, V | |
dc.contributor.author | Lee, FXZ | |
dc.contributor.author | Cunningham, P | |
dc.contributor.author | Walker, GJ | |
dc.contributor.author | Fichter, C | |
dc.contributor.author | Brown, DA | |
dc.contributor.author | Rawlinson, WD | |
dc.contributor.author | Isaacs, SR | |
dc.contributor.author | Mathivanan, V | |
dc.contributor.author | Hoffmann, M | |
dc.contributor.author | Pöhlman, S | |
dc.contributor.author | Mazigi, O | |
dc.contributor.author | Christ, D | |
dc.contributor.author | Dwyer, DE | |
dc.contributor.author | Rockett, RJ | |
dc.contributor.author | Sintchenko, V | |
dc.contributor.author | Hoad, VC | |
dc.contributor.author | Irving, DO | |
dc.contributor.author | Dore, GJ | |
dc.contributor.author | Gosbell, IB | |
dc.contributor.author | Kelleher, AD | |
dc.contributor.author | Matthews, GV | |
dc.contributor.author | Brilot, F | |
dc.contributor.author | Turville, SG | |
dc.date.accessioned | 2022-03-14T23:17:08Z | |
dc.date.available | 2022-03-14T23:17:08Z | |
dc.date.issued | 2021-07-06 | |
dc.identifier.citation | PLoS medicine, 2021, 18, (7), pp. e1003656 | |
dc.identifier.issn | 1549-1277 | |
dc.identifier.issn | 1549-1676 | |
dc.identifier.uri | http://hdl.handle.net/10453/155226 | |
dc.description.abstract | The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design. | |
dc.format | Electronic-eCollection | |
dc.language | eng | |
dc.publisher | Public Library of Science (PLoS) | |
dc.relation.ispartof | PLoS medicine | |
dc.relation.isbasedon | 10.1371/journal.pmed.1003656 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 11 Medical and Health Sciences | |
dc.subject.classification | General & Internal Medicine | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Nucleocapsid Proteins | |
dc.subject.mesh | Antibodies, Viral | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Female | |
dc.subject.mesh | Male | |
dc.subject.mesh | Antibodies, Neutralizing | |
dc.subject.mesh | SARS-CoV-2 | |
dc.title | SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. | |
dc.type | Journal Article | |
utslib.citation.volume | 18 | |
utslib.for | 11 Medical and Health Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Public Health | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2022-03-14T23:17:06Z | |
pubs.issue | 7 | |
pubs.publication-status | Published | |
pubs.volume | 18 | |
utslib.citation.issue | 7 |
Abstract:
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph